First patients dosed in GSK’s Phase III meningitis vaccine trial
The trial will assess the safety, tolerability and immunogenicity of…
The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.